The year in cardiovascular medicine 2020

Michael Aschermann

Cor Vasa 2021, 63(Suppl. 1):5 | DOI: 10.33678/cor.2021.075  

The year in cardiovascular medicine 2020: arrhythmias

Harry J.G.M. Crijns, Frits Prinzen, Pier D. Lambiase, Prashanthan Sanders, Josep Brugada

Cor Vasa 2021, 63(Suppl. 1):6-14  

Summary of the progress in arrhythmias in 2020. RACE4 and ALL-IN indicated that integrated nurse-led care improves outcomes in AF patients.^3,4 The same was reported for early rhythm control therapy¹⁵ and cryoablation as initial AF treatment.^25,26 Subcutaneous ICD was non-inferior to classical transvenous ICD therapy in PRAETORIAN.⁵⁴ One mechanistic study showed that autoantibodies against misexpressed actin, keratin, and connexin-43 proteins create a blood-borne biomarker profile enhancing diagnosis of Brugada syndrome.⁵⁰ Another mechanistic study indicated that transseptal LV pacing yields similar...

The year in cardiovascular medicine 2020: imaging

José Luis Zamorano, Fausto J. Pinto, Jorge Solano-López, Chiara Bucciarelli-Ducci

Cor Vasa 2021, 63(Suppl. 1):15-25  

Raw 3D data were streamed from standard echocardiograph using custom connection to 3D DICOM viewer workstation (CarnaLife Holo, MedApp, Krakow, Poland) for real-time, dynamic 3D rendering and wirelessly transferred into Holo-Lens mixed reality display (Microsoft, Redmond, USA) to overlay non-obstructive 3D data hologram upon reality view. Data were visible as a semitransparent holographic cube positioned in a convenient sector of visual field of echocardio-graphist and shared by interventional cardiologist. From Kasprzak et al.⁷, by permission of OUP on behalf of the ESC.

The year in cardiovascular medicine 2020: valvular heart disease

Javier Bermejo, Andrea Postigo, Helmut Baumgartner

Cor Vasa 2021, 63(Suppl. 1):26-37  

Proposed framework for classifying coexisting mitral regurgitation and severe LV systolic dysfunction. This framework is based on ancillary analyses of randomized clinical trials and prospective validation is pending. ERO: effective regurgitant orifice. EDV: end-diastolic volume. TMVr: transcatheter mitral valve repair.

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Héctor Bueno, Brenda Moura, Patrizio Lancellotti, Johann Bauersachs

Cor Vasa 2021, 63(Suppl. 1):38-51  

During year 2020, we learned new options to better stratify patients with heart failure and preserved left ventricular ejection fraction (HFpEF) (A), the clinical benefit of three new drugs to improve prognosis of patient with heart failure and reduced left ventricular ejection fraction (HFrEF): empagliflozin, vericiguat and omecamtiv mecarbil (B), the potential benefit of a broader utilization of recommended drugs for HFrEF in patients with left ventricular ejection fraction higher than 40% (C), and the potential added clinical benefit of a comprehensive use of recommended drugs for HFrEF (D) in a year marked by the severe acute respiratory syndrome...

The year in cardiovascular medicine 2020: epidemiology and prevention

Ramon Estruch, Luis M. Ruilope, Francesco Cosentino

Cor Vasa 2021, 63(Suppl. 1):52-61  

Cardiovascular disease and cancer continue to be the major causes of death worldwide and the two conditions have more in common than previously acknowledged. In fact, both diseases share many predisposing factors and mecha-nisms, with a common background of low-grade inflammation. Thus, both cardiologists and oncologists should score both cardiovascular and cancer risk factors and develop risk reduction strategies for their patients.

The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care

Borja Ibanez, David Roque, Susanna Price

Cor Vasa 2021, 63(Suppl. 1):62-78  

Highlights of 2020 publications on acute cardiac care–acute coronary syndromes. The statements in this figure are based on individual published articles and do not represent any kind of recommendation. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; COVID-19, coronavirus disease 19; DAPT, dual antiplatelet therapy; FFR, fractional flow reserve; I/R, ischaemia–reperfusion; IRA, infarct-related artery; MI, myocardial infarction; MINOCA, myocardial infarction with non-obstructive coronary arteries; MVD, multivessel disease; MVO, microvascular obstruction; NSTE-ACS, non-ST segment elevation acute coronary syndrome; PCI,...

The year in cardiovascular medicine 2020: interventional cardiology

Fernando Alfonso, Nieves Gonzalo, Fernando Rivero, Javier Escaned

Cor Vasa 2021, 63(Suppl. 1):79-96  

The year in coronary interventions. ACS, acute coronary syndrome; CCS, chronic coronary syndrome; COVID-19: corona-virus disease-19; DEB, drug-eluting balloon; DAPT, dual antiplatelet therapy; ISR, in-stent restenosis.

The year in cardiovascular medicine 2020: digital health and innovation

Charalambos Antoniades, Folkert W. Asselbergs, Panos Vardas

Cor Vasa 2021, 63(Suppl. 1):97-106